Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis

OBJECTIVE: Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce costs and increase treatment capacity (infusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Zachary S., Harkness, Tyler, Blumenthal, Kimberly G., Choi, Hyon K., Stone, John H., Walensky, Rochelle P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231514/
https://www.ncbi.nlm.nih.gov/pubmed/32314553
http://dx.doi.org/10.1002/acr2.11133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231514/
https://www.ncbi.nlm.nih.gov/pubmed/32314553
http://dx.doi.org/10.1002/acr2.11133

Ejemplares similares